Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
2023 expected key events
Regulatory
Cosentyx® HS
decisions
Cosentyx® 2ml Al
Cosentyx® IV
Leqvio® Hypercholesterolemia
Submissions Iptacopan PNH (US/EU/JP)
KisqaliⓇ HR+/HER2- BC (adj)
PluvictoⓇ mCRPC, pre-taxane (US)
Readouts
KisqaliⓇ HR+/HER2- BC (adj)
Iptacopan IgAN Ph3
Iptacopan C3G Ph3
Ph3 starts
Iptacopan in IC-MPGN
LeqvioⓇ CVRR primary prevention
lanalumab in immune thrombocytopenia
lanalumab in systemic lupus erythematosus
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
H1 2023
EU
H2 2023
US
Status update - as of end Q1
US
US
JP, China
US/EU
JP
US
Filing expected in H2
US
NATALEE Ph3 FIR
Primary endpoint met at interim analysis
APPLAUSE-IgAN Ph3
APPEAR-C3G Ph3
Ph3
Ph3
Ph3
Ph3
VICTORION-1P initiated
1L (VAYHIT1) and 2L (VAYHIT2) initiated
SIRIUS-SLE 1 and 2 initiated
HS hidradenitis suppurativa.
C3G
PNH - paroxysmal nocturnal hemoglobinuria.
complement 3 Glomerulopathy.
mCRPC metastatic castration-resistant prostate cancer. FIR - first interpretable results. IgAN - immunoglobulin A nephropathy.
IC-MPGN - immune complex membranoproliferative glomerulonephritis.
32 Investor Relations | Q1 2023 Results
INNOVATION
U NOVARTIS | Reimagining MedicineView entire presentation